---
document_datetime: 2025-11-23 13:11:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/celvapan.html
document_name: celvapan.html
version: success
processing_time: 0.109188
conversion_datetime: 2025-12-29 21:24:53.111422
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Celvapan

[RSS](/en/individual-human-medicine.xml/66141)

##### Withdrawn

This medicine's authorisation has been withdrawn

influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated) Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 21 November 2016, the European Commission withdrew the marketing authorisation for Celvapan (pandemic influenza vaccine (H1N1) (whole virion, inactivated, prepared in cell culture)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Nanotherapeutics Bohumil sro, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Celvapan was granted marketing authorisation in the EU on 6 October 2009 for prophylaxis of influenza caused by A/H1N1v 2009 virus. The marketing authorisation was initially valid for a 5-year period and was then renewed with unlimited validity on 26 February 2015. The product has not been marketed in the EU since 2010.

Nanotherapeutics Bohumil sro is the marketing authorisation holder for another pandemic vaccine, Pandemic Influenza Vaccine H5N1 Baxter AG, which is authorised in the EU for pandemic preparedness. Nanotherapeutics Bohumil sro will maintain the marketing authorisation for Pandemic Influenza Vaccine H5N1 Baxter AG.

The European Public Assessment Report (EPAR) for Celvapan is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Celvapan : EPAR - Summary for the public

English (EN) (549.66 KB - PDF)

**First published:** 08/10/2009

**Last updated:** 21/12/2016

[View](/en/documents/overview/celvapan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-969)

български (BG) (633.17 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/bg/documents/overview/celvapan-epar-summary-public_bg.pdf)

español (ES) (569.5 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/es/documents/overview/celvapan-epar-summary-public_es.pdf)

čeština (CS) (612.73 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/cs/documents/overview/celvapan-epar-summary-public_cs.pdf)

dansk (DA) (550.05 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/da/documents/overview/celvapan-epar-summary-public_da.pdf)

Deutsch (DE) (549.15 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/de/documents/overview/celvapan-epar-summary-public_de.pdf)

eesti keel (ET) (549.03 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/et/documents/overview/celvapan-epar-summary-public_et.pdf)

ελληνικά (EL) (659.25 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/el/documents/overview/celvapan-epar-summary-public_el.pdf)

français (FR) (572.11 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/fr/documents/overview/celvapan-epar-summary-public_fr.pdf)

hrvatski (HR) (568.03 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/hr/documents/overview/celvapan-epar-summary-public_hr.pdf)

italiano (IT) (553.19 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/it/documents/overview/celvapan-epar-summary-public_it.pdf)

latviešu valoda (LV) (592.85 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/lv/documents/overview/celvapan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (592.49 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/lt/documents/overview/celvapan-epar-summary-public_lt.pdf)

magyar (HU) (607.23 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/hu/documents/overview/celvapan-epar-summary-public_hu.pdf)

Malti (MT) (597.98 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/mt/documents/overview/celvapan-epar-summary-public_mt.pdf)

Nederlands (NL) (570.54 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/nl/documents/overview/celvapan-epar-summary-public_nl.pdf)

polski (PL) (634.29 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/pl/documents/overview/celvapan-epar-summary-public_pl.pdf)

português (PT) (547.79 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/pt/documents/overview/celvapan-epar-summary-public_pt.pdf)

română (RO) (571.44 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/ro/documents/overview/celvapan-epar-summary-public_ro.pdf)

slovenčina (SK) (612.83 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/sk/documents/overview/celvapan-epar-summary-public_sk.pdf)

slovenščina (SL) (624.2 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/sl/documents/overview/celvapan-epar-summary-public_sl.pdf)

Suomi (FI) (570.2 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/fi/documents/overview/celvapan-epar-summary-public_fi.pdf)

svenska (SV) (571.48 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/sv/documents/overview/celvapan-epar-summary-public_sv.pdf)

## Product information

Celvapan : EPAR - Product Information

English (EN) (687.18 KB - PDF)

**First published:** 15/11/2009

**Last updated:** 21/12/2016

[View](/en/documents/product-information/celvapan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-479)

български (BG) (1.44 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/bg/documents/product-information/celvapan-epar-product-information_bg.pdf)

español (ES) (700.53 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/es/documents/product-information/celvapan-epar-product-information_es.pdf)

čeština (CS) (1.12 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/cs/documents/product-information/celvapan-epar-product-information_cs.pdf)

dansk (DA) (715.13 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/da/documents/product-information/celvapan-epar-product-information_da.pdf)

Deutsch (DE) (704.69 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/de/documents/product-information/celvapan-epar-product-information_de.pdf)

eesti keel (ET) (683.21 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/et/documents/product-information/celvapan-epar-product-information_et.pdf)

ελληνικά (EL) (1.44 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/el/documents/product-information/celvapan-epar-product-information_el.pdf)

français (FR) (703.87 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/fr/documents/product-information/celvapan-epar-product-information_fr.pdf)

hrvatski (HR) (720.88 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/hr/documents/product-information/celvapan-epar-product-information_hr.pdf)

íslenska (IS) (693.1 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/is/documents/product-information/celvapan-epar-product-information_is.pdf)

italiano (IT) (699.23 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/it/documents/product-information/celvapan-epar-product-information_it.pdf)

latviešu valoda (LV) (1.18 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/lv/documents/product-information/celvapan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (770.71 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/lt/documents/product-information/celvapan-epar-product-information_lt.pdf)

magyar (HU) (1.08 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/hu/documents/product-information/celvapan-epar-product-information_hu.pdf)

Malti (MT) (1.14 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/mt/documents/product-information/celvapan-epar-product-information_mt.pdf)

Nederlands (NL) (697.18 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/nl/documents/product-information/celvapan-epar-product-information_nl.pdf)

norsk (NO) (686.07 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/no/documents/product-information/celvapan-epar-product-information_no.pdf)

polski (PL) (1.14 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/pl/documents/product-information/celvapan-epar-product-information_pl.pdf)

português (PT) (697.57 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/pt/documents/product-information/celvapan-epar-product-information_pt.pdf)

română (RO) (781.1 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/ro/documents/product-information/celvapan-epar-product-information_ro.pdf)

slovenčina (SK) (1.11 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/sk/documents/product-information/celvapan-epar-product-information_sk.pdf)

slovenščina (SL) (1.06 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/sl/documents/product-information/celvapan-epar-product-information_sl.pdf)

Suomi (FI) (690.48 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/fi/documents/product-information/celvapan-epar-product-information_fi.pdf)

svenska (SV) (693.11 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

21/12/2016

[View](/sv/documents/product-information/celvapan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0031 30/11/2015

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Celvapan : EPAR - All Authorised presentations

English (EN) (477.52 KB - PDF)

**First published:** 08/10/2009

**Last updated:** 21/12/2016

[View](/en/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-707)

български (BG) (570 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/bg/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_bg.pdf)

español (ES) (478.2 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/es/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (559.31 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/cs/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (477.83 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/da/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (478.19 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/de/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (478.75 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/et/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (563.99 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/el/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_el.pdf)

français (FR) (478.69 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/fr/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (496.33 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/hr/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (477.98 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/is/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (477.68 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/it/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (560.32 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/lv/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (547.85 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/lt/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (558.86 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/hu/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (561.05 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/mt/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (478.02 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/nl/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (478.33 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/no/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_no.pdf)

polski (PL) (566.34 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/pl/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_pl.pdf)

português (PT) (478.44 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/pt/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_pt.pdf)

română (RO) (546.88 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/ro/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (558.97 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/sk/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (527.15 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/sl/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (478.01 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/fi/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (478.01 KB - PDF)

**First published:**

08/10/2009

**Last updated:**

21/12/2016

[View](/sv/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Celvapan Active substance whole virion influenza vaccine, inactivated containing antigen of strain A/California/07/2009 (H1N1)v International non-proprietary name (INN) or common name influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated) Therapeutic area (MeSH)

- Disease Outbreaks
- Influenza, Human
- Immunization

Anatomical therapeutic chemical (ATC) code J07BB01

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Prophylaxis of influenza caused by A(H1N1)v 2009 virus.

Celvapan should be used in accordance with official guidance.

## Authorisation details

EMA product number EMEA/H/C/000982 Marketing authorisation holder

Nanotherapeutics Bohumil, s.r.o.

Bohumill38

Marketing authorisation issued 04/03/2009 Withdrawal of marketing authorisation 21/11/2016 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Celvapan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (603.8 KB - PDF)

**First published:** 15/11/2009

**Last updated:** 21/12/2016

[View](/en/documents/procedural-steps-after/celvapan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Celvapan-H-C-982-II-0019-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/664781/2012

English (EN) (761.69 KB - PDF)

**First published:** 25/10/2012

**Last updated:** 21/12/2016

[View](/en/documents/variation-report/celvapan-h-c-982-ii-0019-g-epar-assessment-report-variation_en.pdf)

Celvapan-H-C-982-II-0017-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/283690/2011

English (EN) (662.79 KB - PDF)

**First published:** 25/10/2012

**Last updated:** 21/12/2016

[View](/en/documents/variation-report/celvapan-h-c-982-ii-0017-g-epar-assessment-report-variation_en.pdf)

Celvapan-H-C-982-SW-0014  : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/487986/2010

English (EN) (593.57 KB - PDF)

**First published:** 04/10/2010

**Last updated:** 21/12/2016

[View](/en/documents/variation-report/celvapan-h-c-982-sw-0014-epar-assessment-report-variation_en.pdf)

Celvapan-H-C-982-II-0012 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/257008/2010

English (EN) (593.57 KB - PDF)

**First published:** 02/06/2010

**Last updated:** 21/12/2016

[View](/en/documents/variation-report/celvapan-h-c-982-ii-0012-epar-assessment-report-variation_en.pdf)

Celvapan-H-C-982-II-0009 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/843807/2009

English (EN) (757.83 KB - PDF)

**First published:** 15/01/2010

**Last updated:** 22/12/2016

[View](/en/documents/variation-report/celvapan-h-c-982-ii-0009-epar-assessment-report-variation_en.pdf)

Celvapan-H-C-832-II-0006 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/CHMP/733392/2009

English (EN) (596.65 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 22/12/2016

[View](/en/documents/variation-report/celvapan-h-c-832-ii-0006-epar-assessment-report-variation_en.pdf)

Celvapan-H-C-982-PU-0002 : EPAR - Assessment Report - Variation

Reference Number: EMEA/CHMP/629184/2009

English (EN) (1.75 MB - PDF)

**First published:** 09/10/2009

**Last updated:** 21/12/2016

[View](/en/documents/variation-report/celvapan-h-c-982-pu-0002-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Celvapan : EPAR - Public assessment report

English (EN) (1.27 MB - PDF)

**First published:** 08/04/2009

**Last updated:** 21/12/2016

[View](/en/documents/assessment-report/celvapan-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use summary of positive opinion for Celvapan

Reference Number: EMEA/CHMP/657005/2008

English (EN) (487.96 KB - PDF)

**First published:** 18/12/2008

**Last updated:** 22/12/2016

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-celvapan_en.pdf)

**This page was last updated on** 21/12/2016

## Share this page

[Back to top](#main-content)